Market Signal Briefing

Empowering Webex users with seamless CRM integration and advanced analytics for improved productivity and insights

October 01, 2025 03:07 ET

 | Source:

CallTower, Inc.

SALT LAKE CITY, UT, ROCHESTER, NY, MONTREAL, QC, LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CallTower, a global leader in cloud-based unified communications and contact center solutions, announced today the addition of two of its signature solutions, CT Unite CRM Integration and CallTower Analytics, to CallTower’s Webex by Cisco® platform. This strategic development provides Webex users with powerful tools designed to streamline communication, enhance productivity, and deliver actionable business insights directly within their collaboration environment. 

The integration of CT Unite CRM Integration with Webex empowers users by embedding communication controls directly into their CRM systems. This fusion of platforms eliminates the need to switch between applications, allowing teams to manage calls, access customer data, and log interactions seamlessly. By unifying these critical business tools, organizations can significantly improve workflow efficiency and elevate the customer experience. 

In addition, the availability of CallTower Analytics for Webex offers organizations comprehensive visibility into their Webex Calling communication patterns. This powerful data solution provides detailed reporting and intuitive dashboards, transforming raw call data into actionable intelligence. Businesses can now leverage these insights to optimize resource allocation, identify trends, and make informed decisions that drive growth and improve operational performance. 

“At CallTower, our mission is to empower businesses with innovative solutions to drive productivity and growth,” said William Rubio, Chief Revenue Officer at CallTower. “Adding CT Unite and CallTower Analytics to Webex enables our customers to unlock even greater value from their collaboration environment—seamlessly connecting their CRM and leveraging analytics for data driven insights.” 

These additions underscore CallTower's commitment to innovation and customer success. By continuously enhancing its solution portfolio and integrating with leading platforms like Webex, CallTower ensures its customers are equipped with the most advanced and effective communication technologies available. The new integrations are designed to help businesses maximize their investment in the Webex platform while achieving greater operational excellence. 

About CallTower 

CallTower is at the forefront of transforming global communication, redefining how businesses connect and collaborate across the globe. Since 2002, CallTower has grown into a global leader in enterprise-class cloud communications and collaboration solutions, empowering businesses to thrive in the digital age. Leveraging advanced technologies like Microsoft® Teams Operator Connect, Teams Direct Routing, GCC High Teams Direct Routing, Webex by Cisco®, Zoom Phone, and AI-powered contact center solutions, such as Webex Contact Center, Five9, Genesys and more.  CallTower delivers seamless and reliable connectivity tailored to the unique needs of enterprises worldwide. CallTower empowers business communications by integrating features like one-click failover, advanced analytics, seamless CRM integration, and cutting-edge AI—redefining operational efficiency. 

In 2025, CallTower acquired North America’s trusted contact center expert, Inoria, amplifying its CCaaS and CX capabilities. Inoria drives the evolution of contact center operations by offering personalized optimization, implementation, and integration services powered by Conversational AI and advanced analytics. Together, CallTower and Inoria deliver actionable insights, enhanced customer experiences, and cutting-edge solutions that guide enterprises through their digital transformation journeys. 

 With a vision focused on innovation and a commitment to excellence, CallTower continues to advance cloud communications, empowering businesses across the globe to achieve unparalleled success.

Contact Data

Kade Herbert
CallTower, Inc.
8003475444
[email protected]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in EQX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) has announced positive results from its Phase 3 pediatric FORTIS trial of ferric maltol (ACCRUFeR).

The trial tested children and adolescents with iron deficiency using ferric maltol against ferrous sulfate, and, the data was presented at the American Association of Pediatrics conference on 29 September, in Denver.

"This first publication of results confirming the safety and effectiveness of ferric maltol treatment in children as young as 2 months is an important milestone for Shield to further the expansion of ACCRUFeR® in this additional patient population who can benefit from a much needed safe and effective oral iron treatment," said Shield Therapeutics vice president Dr Jackie Mitchell.

Clinically significant improvements in haemoglobin were observed across all groups. No patients discontinued ferric maltol due to adverse events, while one discontinuation occurred in the ferrous sulfate group.

Treatment-related adverse events were reported in 6.5% of ferric maltol patients versus 13% with ferrous sulfate.

VALLOUREC SECURES A NEW ORDER WITH PETROBRAS FOR SUBMAGNÉTICO FREE FLOW®

Meudon (France), October 1st 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces a new order for SUBMAGNÉTICO FREE FLOW®, its Oil Country Tubular Goods (OCTG) solution designed to prevent inorganic scaling in production strings. This new order signed with the Brazilian operator, Petrobras, covers the production and installation of more than 30 units, to be delivered and installed in Brazil’s offshore pre-salt fields.

SUBMAGNÉTICO FREE FLOW® is a breakthrough technology that applies a magnetic field on the extracted fluid and reduces the formation of inorganic scaling on the production string. With this solution, operators are expected to achieve significant cost reduction via reduced well cleaning interventions, reduced consumption of scale inhibitors, and a significant reduction in production downtime.

Co-developed with Petrobras, SUBMAGNÉTICO FREE FLOW® has successfully passed all qualification tests, including vibration, shock and pressure tests, as well as API and ISO connection tests.

Jérôme Favre, Senior Vice President of OCTG, Services and Accessories declared: “This new order confirms the growing adoption of SUBMAGNÉTICO FREE FLOW® as a standard anti-scaling technology for offshore production. It also demonstrates Vallourec’s ability to co-develop smart, safe, and cost-effective solutions tailored to our clients’ most critical challenges.”

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec’s pioneering spirit and cutting-edge R&D open new technological frontiers. With close to 13,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand- in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible.

Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service.

In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1.

For further information, please contact:

Investor relations:
Connor Lynagh
Tel: +1 (713) 409-7842

[email protected] relations: Taddeo
Romain Grière
Tel: +33 (0)7 86 53 17 29

[email protected] Nicolas Escoulan
Tel: +33 (0)6 42 19 14 74
[email protected]

Individual shareholders:
Toll Free number (From France): 0 805 65 10 10 [email protected]

PR_Submagnético_EN_final

This report is from this week's CNBC's UK Exchange newsletter. Like what you see? You can subscribe here.

The dispatchThere is an old British saying about buses: you wait ages for one and then two arrive at once.

Pharmaceuticals analysts experienced something similar on Monday as the big two U.K. drugmakers — GSK and AstraZeneca — delivered major announcements.

GSK said Emma Walmsley, its CEO of nine years, who steered it through its demerger (its former consumer healthcare arm is now a separate company called Haleon), will leave at the end of the year. Her successor is Luke Miels, currently chief commercial officer, was poached from AZ amid acrimony eight years ago.

AZ, meanwhile, announced plans to "harmonise its share listing structure to deliver a global listing for global investors in a global company". 

In practice, that means delisting its American Depositary Receipts (ADRs) from the Nasdaq, replacing them with a direct listing of ordinary shares on the New York Stock Exchange.

ADRs are tradable certificates issued by U.S. banks representing a specific number of shares (usually one) of a foreign company. They tend to be less liquid than fully listed stocks — and that deters some investors.

The move was welcomed by investors, with shares up 0.8% on Monday. It should bring in new U.S. investors, especially if — although this is not a given — AZ eventually gains membership of the S&P 500.

Defections from the UKAt first blush, it confirms fears first aired when, in July, The Times reported that CEO Pascal Soriot wanted to move AZ's stock market listing to the U.S.

The British newspaper said Soriot, who today marks 13 years at the helm, had spoken privately of doing this on several occasions and had even discussed moving AZ's domicile. Soriot fanned the flames when, at subsequent results briefings, he did not deny the report and even called AZ a "very American company." AZ is among several big pharma companies to recently pause or postpone U.K. investments amid frustration at the country's drug-pricing regime.

Accordingly, some interpret this as another blow to the London Stock Exchange (LSE), which is indeed how it was reported locally. A clutch of big names, all former FTSE 100 members, have moved their primary listing away from the U.K. lately.

The defections began when, in 2021, BHP Group (previously BHP Billiton) — at the time the FTSE's most valuable company — announced plans to switch from a dual-listed structure, in which its shares were listed in both the U.K. and Australia, to a single primary listing on the Australian Securities Exchange (ASX). This was essentially a cost-saving and simplification exercise and few alarm bells rang at the time, not least because BHP retained a standard listing on the LSE, allowing British investors to remain exposed to the business. Moreover, BHP had no real assets in the U.K., other than a head office.

The following year, the plumbing and heating products distributor Ferguson — a U.K. stock market stalwart for decades under its former name of Wolseley — moved its primary listing to New York. Again, this was no surprise, since North America by then accounted for more than 90% of its sales.

There was still no panic when, in March 2023, CRH — the world's biggest building materials supplier — chose to switch to New York. After all, having only had a primary listing in London for 12 years, CRH was essentially an Irish company generating more than three-quarters of its earnings in the U.S.

There was more disquiet when Flutter Entertainment, owner of successful betting and gaming businesses such as Paddy Power, Betfair, Sky Betting & Gaming and the U.S. business FanDuel, said it was considering moving its main listing to New York. It has since done so.

This was altogether more serious as Flutter, the Irish-founded Paddy Power aside, was essentially British and a big player in its domestic market. Compounding concerns, later that year, the Cambridge-based chip designer Arm Holdings opted to list on Nasdaq instead of the LSE on its return to the stock market.

Since then, the Anglo-German tour operator TUI has moved from a dual listing in London and Frankfurt to a single one in the latter, while the FTSE 100 plant and equipment hire company Ashtead — named after the Surrey village where it was founded — has announced plans to move its primary listing from London to New York. This again reflects the fact that 90% of its business is now in North America.

The bad news, like the London drizzle, has kept on coming: Just Eat Takeaway said last December it would move from a dual listing in London and Amsterdam to a single one in the latter; the same location was chosen in February this year by Unilever for its demerged ice cream business.

Fast-fashion giant Shein was recently reported to have chosen Hong Kong over London for its forthcoming Initial Public Offering, and Wise (formerly Transferwise), a fintech founded in London by two Estonian entrepreneurs and now valued at more than £11 billion ($14.78 billion), received shareholder approval in July to move its primary listing from London to New York.

AZ a different case?AZ's decision, though, may not be as bad as it looks. It was at pains to stress its "current status as a U.K. listed, headquartered and tax resident company" would not change and that this was all about attracting a broader mix of global investors and better access to New York's larger pools of capital.

Nor does this look to be a move in search of a higher stock rating: AZ's price-to-earnings ratio exceeds not only those of European peers like Novo Nordisk and Roche, but also several U.S. peers including Pfizer, Bristol-Myers Squibb and Merck.

The British government should not get complacent, however. This move potentially eases a full switch of listing to New York should Soriot's frustrations at the U.K. finally boil over.

Rachel Reeves, the country's chancellor, could prove she is alert to the risk posed to the London market by removing Stamp Duty Reserve Tax, the anachronistic levy of 0.5% applied on all share purchases.

But — as it raises £3 billion annually for the Treasury — I wouldn't bet on this.

Top TV picks on CNBCwatch now

Louise Hellem, chief economist at the CBI, discusses the Chancellor's options ahead of the U.K. government's upcoming Budget at the Labour Party Conference in Liverpool.

watch now

Ruth Curtice, chief executive of Resolution Foundation, discusses potential plans to increase personal taxes and the outlook for migration at the Labour Party Conference in Liverpool.

watch now

Ian King joins Squawk Box Europe on location in Canary Wharf to discuss why the U.K. isn't good at helping startups to scale up, even though it's created more "unicorns" than any other country outside the U.S. and China.

— Holly Ellyatt

Need to knowUK at a 'fork in the road,' Prime Minister Keir Starmer warns. At the Labour Party's annual conference in Liverpool, Starmer said Tuesday that Britain is facing "renewal or decline." His comments come as the right-wing party Reform UK appears to be leading in the polls.

Bank bosses in the UK are calling for policy stability. Finance Minister Rachel Reeves' Autumn Budget is scheduled for Nov. 26. Ahead of it, CEOs from Barclays, Citi and J.P. Morgan told CNBC that the banking sector, while seeing an upturn, needs great clarity from the government.

Barclays CEO doubles down on the UK. That's despite the prospect of the government increasing taxes on the banking sector in its upcoming budget. C.S. Venkatakrishnan, the bank's chief, said the tax would "stifle growth," but still called the U.K. the bank's "home."

— Yeo Boon Ping

Quote of the weekWe have a modern industrial strategy, which is taking seven, eight sectors in the economy, and giving a 10-year plan for each of them. Businesses ... can see what the policy framework is going to be for a 10-year period.

— Peter Kyle, U.K. secretary of state of business and trade

In the marketsLondon-listed stocks have advanced over the past week, with the FTSE 100 up 1.38% from Sept. 23. It ended Tuesday at 9,350.43 points, with concerns surrounding a potential U.S. government shutdown weighing on investors' minds.

The yield on 10-year gilts ticked higher from 4.695% a week ago to 4.701% on Tuesday afternoon, as U.K. borrowing came into sharp focus during Chancellor Rachel Reeves' speech at the Labour party conference in Liverpool.

Meanwhile, sterling dropped 0.71% against the dollar over the last week, reaching $1.34.

Stock Chart IconStock chart icon

The performance of the Financial Times Stock Exchange 100 Index over the past year.

— Katrina Bishop

Coming upOct. 1: Nationwide Housing Prices

Oct. 6: U.K. new car sales data

Oct. 7: Halifax House Price Index

— Holly Ellyatt

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in IDT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

By Reuters

October 1, 20255:53 AM UTCUpdated ago

TotalEnergies signs at a petrol station in Nice, France, October 10, 2022. REUTERS/Eric Gaillard Purchase Licensing Rights, opens new tab

CompaniesOSLO, Oct 1 (Reuters) - Vaar Energi

(VAR.OL), opens new tab, majority owned by Italy's Eni

(ENI.MI), opens new tab, said on Wednesday it has agreed to buy TotalEnergies'

(TTEF.PA), opens new tab stake in Norway's Ekofisk PPF oilfield, lifting Vaar's stake to 52.3% from 12.4%.

Sign up here.

Reporting by Terje Solsvik; Editing by Muralikumar Anantharaman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

-

LONDON--(BUSINESS WIRE)--Lazard, Inc. (NYSE: LAZ) today announced the appointment of Cyrille Cotte as Managing Director and Head of Insurance for its European Financial Institutions Group (FIG), based in London and working across Europe with regional Co-Heads of Financial Services Coverage Nick Millar and Corso Bavagnoli.

Cyrille joins Lazard from Evercore, where he was a Partner and Senior Managing Director in the European Financial Institutions Group. Over his career, he has focused on advising a broad range of insurers and other financial services firms on mergers, acquisitions, capital raising, and strategic initiatives across Europe and internationally.

“Cyrille brings an impressive depth of knowledge and experience in the insurance and broader financial institutions sector,” said Cyrus Kapadia, Co-Head of European Investment Banking at Lazard. “He is widely respected for his work and leadership on complex cross-border transactions, and his addition will further strengthen our ability to support our clients in seizing the right opportunities and navigating a rapidly changing global financial landscape.”

“I am excited to welcome Cyrille in our European FIG team,” said Jean-Louis Girodolle, Co-Head of European Investment Banking at Lazard. “His recognised expertise and trusted relationships with an extensive range of global clients will enhance our ability to provide thoughtful and creative solutions for the insurance sector across the financial services spectrum.”

“I’m excited to join Lazard and contribute to the firm’s strong reputation for providing independent, strategic advice,” said Cyrille Cotte. “I look forward to collaborating with my new colleagues across geographies, sectors and products to help our clients achieve their strategic ambitions in today’s fast changing financial environment.”

With over 20 years of experience, Cyrille has advised insurers and financial institutions on numerous landmark transactions globally, including mergers, acquisitions, sales, public market transactions, capital raisings and strategic partnerships. His track record includes leading roles in the acquisition of German life insurer Viridium by Allianz, BlackRock, and T&D Holdings; Athora’s sale of its Irish Life business; and MetLife’s sale of its UK Pension Risk Transfer business. He has also worked on AXA’s acquisition of HSBC’s insurance operations in Asia and Latin America.

Before joining Evercore in 2016, Cyrille held senior roles at Citi’s EMEA Financial Institutions Group, Macquarie, Fox-Pitt Kelton, and EY in London and Paris. He holds a Master’s in Management from EDHEC Business School in Lille, France.

About Lazard

Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.

LAZ-CPE

More News From Lazard, Inc.

Back to Newsroom

Gold's special quality as an all-purpose, antianxiety asset for investors is evident in its performance. The metal is up 43% this year alone, compared with 14% for the S&P 500.

- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -

- Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium -

, /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present ten abstracts from our portfolio and advancing pipeline at the European Society for Medical Oncology (ESMO) congress taking place from 17-21 October 2025, including new data for PADCEV™ (enfortumab vedotin) plus pembrolizumab in muscle-invasive bladder cancer (MIBC) which will be presented in an ESMO Presidential Symposium on 18 October. In prostate cancer, we are sharing final best-in-class overall survival data for XTANDI™ (enzalutamide) in high-risk, biochemically recurrent non-metastatic hormone sensitive disease, plus encouraging data for our next-generation bispecific T cell engager ASP2138 in solid tumors, demonstrating continued leadership in CLDN18.2-targeted precision medicine.

Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development, Astellas
"Astellas focuses on some of the most complex and devastating cancers. These ESMO data demonstrate our 'bench to bedside' approach in action – from deep disease biology to measurable improvements in patient outcomes. We're proud to share breakthrough new survival data in muscle-invasive bladder cancer and overall survival data in hormone sensitive prostate cancer, which reflect potentially practice-changing advances that could transform outcomes for patients who need them most. We also continue to advance innovation in gastric and gastroesophageal junction cancer with new clinical data for our next-generation investigational bispecific T cell engager."

Highlights from Astellas at ESMO 2025 will include:

Data from the Phase 3 EV-303 (also known as KEYNOTE-905) clinical trial which will be featured in an ESMO Presidential Symposium, evaluating enfortumab vedotin in combination with pembrolizumab as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with MIBC who are not eligible for or declined cisplatin-based chemotherapy.
Long-term follow-up data from the EV-302 clinical trial exploring the utility of enfortumab vedotin in combination with pembrolizumab for patients with challenging baseline characteristics, including older patients with locally advanced or metastatic urothelial cancer and those with comorbidities such as diabetes and chronic kidney disease.
Final data from the Phase 3 EMBARK trial assessing overall survival with enzalutamide in combination with leuprolide and as monotherapy in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as non-metastatic castration-sensitive prostate cancer or nmCSPC) with high-risk biochemical recurrence.
First clinical data from Astellas' investigational CLDN18.2-targeted, next-generation bispecific CD3 T cell engager ASP2138, both as a monotherapy and in combination with standard of care therapy.

Astellas Presentations at ESMO Congress 2025

Enfortumab vedotin

Presentation Title

Presenter

Presentation Details

Perioperative enfortumab vedotin plus pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study

C. Vulsteke

Type: Presidential Symposium 1

Abstract Number: LBA2

Date: October 18,
16:52 - 17:04 CEST

Enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer: An exploratory analysis in older patients and those with comorbidities from EV-302

N. Mar

Type: Poster

Abstract Number: 3073P

Date: October 18,
12:00-12:45 CEST

Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: Results from a cohort of the EV-202 trial

P.L. Swiecicki

Type: Mini oral

Abstract Number: 1329 MO

Date: October 19,
17:38-17:43 CEST

EV-103 Cohort K: Efficacy and safety of enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer with a median follow-up of ≈3.5 y

T.W. Friedlander

Type: Poster

Abstract Number: 3074P

Date: October 18,
12:00-12:45 CEST

Real-world use of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and immunotherapy in France

A. Fléchon

Type: ePoster

Abstract Number: 3111eP

Date: October 18, 12:00-12:45 CEST

Enzalutamide 

Presentation Title

Presenter

Presentation Details

Overall survival in EMBARK, a phase 3 randomised trial of enzalutamide or placebo plus leuprolide and enzalutamide monotherapy in patients with nonmetastatic hormone-sensitive prostate cancer with biochemical recurrence at high risk for metastasis

S.J. Freedland

Type: Proffered Paper

Abstract Number: LBA87

Date: October 19,
10:55-11:05 CEST

Baseline features and metastasis-free survival by prior definitive treatment in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis

N.D. Shore

Type: Poster

Abstract Number: 2461P

Date: October 18,
12:00-12:45 CEST

Pipeline

Presentation Title

Presenter

Presentation Details

ASP2138 monotherapy in patients with (CLDN18.2)+, advanced solid tumors: Phase 1/1b trial

K. Shitara

Type: Poster

Abstract Number: 2137P

Date: October 19,
12:00-12:45 CEST

ASP2138 monotherapy or in combination with pembrolizumab and mFOLFOX6 or with ramucirumab and paclitaxel in (CLDN18.2)+ locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Phase 1/1b trial

F. Dayyani

Type: Poster

Abstract Number: 2136P

Date: October 19,
12:00-12:45 CEST

Phase 1 trial of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer

J. Avitia

Type: Poster

Abstract Number: 2443P

Date: October 18,
12:00-12:45 CEST

About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

About the Pfizer, Astellas and Merck Collaboration

Seagen and Astellas previously entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's KEYTRUDA™ (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).

About XTANDI and the Pfizer/Astellas Collaboration
In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE:PFE), and Astellas (TSE: 4503) entered into a commercial agreement to jointly develop and commercialize XTANDI® (enzalutamide) in the United States, while Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing the product outside the United States. Pfizer receives alliance revenues as a share of U.S. profits and receives royalties on sales outside the U.S.

Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

SOURCE Astellas Pharma Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

October 01, 2025 02:00 ET

 | Source:

Diversified Energy PLC

Diversified Energy Announces Proposed Move of Primary Listing to the New York Stock Exchange

Diversified Will Retain UK Listing on the International Secondary Listing Category

Move Expected to Enhance Trading Liquidity, Increase Visibility with Investors, and Provide Strategic Capital Markets Benefits to Accelerate Growth

BIRMINGHAM, Ala., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC (the “Company”) (LSE:DEC, NYSE:DEC) announced today that its Board of Directors, having evaluated the Company’s optimal public company listing venue, intends to move the Company’s primary listing to the New York Stock Exchange (“NYSE”) while retaining a secondary listing on the London Stock Exchange (“LSE”).

Today, the Company is substantially a US business, reporting in US dollars, with all the Company’s operating profit derived from its US operations, which is also the sole growth market for the business. The Company’s executive management team and operational headquarters are based in the US, all of its employees reside in the US and all its assets are located in the US.

Additionally, as of June 30, 2025, over 65% of the Company’s outstanding shares were held by US resident investors. The Company will start filing customary SEC financial statements and periodic reports as a US domestic filer with its year-end 2025 financial results.

The Board has been evaluating the optimal primary listing venue for the Company in the context of its business strategy for the benefit of all its stakeholders. In December 2023, the Company undertook an additional listing of its shares on the NYSE to complement its existing LSE listing. At this time, the Board has concluded that the US market is the natural long-term primary listing venue for the Company and that moving to a US primary listing, while retaining a secondary UK listing on the ESICC Category, is in the best interests of its shareholders.

In arriving at this conclusion, the Board considered several factors and potential benefits, including:

alignment of the primary listing venue with the Company’s business activity, leadership team, and employee baseincreased overall liquidity in the Company’s shares, given access to deeper US capital marketsincreased exposure to US investors through a primary US listing, including additional access to passive investment pools of capitalexpanded Company profile and access to high-quality equity investorssimplified share ownership for the wider employee base of the Company and expanded access to the recruitment and retention of top US talentoptimized positioning of the Company for inclusion in premier US equity indices and Exchange Traded Fundsretention of a secondary listing on the LSE to facilitate trading liquidity for non-US shareholder base The proposed venue change will be implemented by way of a UK scheme of arrangement which will require a formal vote by shareholders of the Company at a general meeting (“General Meeting”) to be approved by a majority in number of the registered shareholders voting in person or by proxy, representing 75% in value of the shares voted. It is currently expected that a shareholder circular containing details of the proposals will be published and that the General Meeting will take place in the coming weeks. Subject to shareholders voting in favor of the proposals at the General Meeting, the Board expects that the scheme of arrangement will take effect during the fourth quarter of 2025, after which the shares are expected to trade on the NYSE and on the equity shares (commercial companies) category of the Official List of the FCA (the “ESICC Category”) and the Main Market of the LSE.

Further announcements will be made in due course as the process advances.

For further information, please contact:

Diversified Energy Company PLC +1 973 856 2757Doug Kris [email protected] Vice President, Investor Relations & Corporate Communications www.div.energy   FTI Consulting [email protected]. & UK Financial Public Relations      About Diversified Energy Company PLC

Diversified is a leading publicly traded energy company focused on natural gas and liquids production, transport, marketing, and well retirement. Through our unique differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value.

Forward-Looking Statements

This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). These forward-looking statements, which may contain the words "anticipate", "believe", "intend", "estimate", "expect", "may", "will", "seek", "continue", "aim", "target", "projected", "plan", "goal", "achieve", “opportunity” and words of similar meaning, reflect the Company's beliefs and expectations and are based on numerous assumptions regarding the Company's present and future business strategies and the environment the Company will operate in and are subject to risks and uncertainties that may cause actual results to differ materially. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include statements regarding the intentions, beliefs or current expectations of management or the Company concerning, among other things, statements regarding the reorganization, our transition to reporting as a US domestic filer, the General Meeting and the move of our primary listing to the NYSE and the retention of a secondary listing on the LSE, including the timing for such events, future communications regarding such events, their benefits and impact, descriptions of anticipated future liquidity and access to capital, and the inclusion of our equity securities in certain US equity indices or exchange traded funds. No representation is made that any of these statements or forecasts will be achieved. The reorganization and move to a primary listing may not be realized on the terms described in this release or at all. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, including risks relating to the proposed reorganization, including the requirements for shareholder and court approvals, the move to a US primary listing, the Company’s transition to reporting as a US domestic filer, the potential that anticipated benefits such as enhanced liquidity, index eligibility and broader investor access may not be realized, as well as the risk factors described in the "Risk Factors" section in the Company's Annual Report and Form 20-F for the year ended December 31, 2024, filed with the SEC, and also including other important factors that could cause actual results to differ materially from those projected. Forward-looking statements speak only as of their date and neither the Company nor any of its directors, officers, employees, agents, affiliates or advisers expressly disclaim any obligation to supplement, amend, update or revise any of the forward-looking statements made herein, except where it would be required to do so under applicable law. As a result, you are cautioned not to place undue reliance on such forward-looking statements.

Item 1 of 2 Aishwarya Rai poses on the red carpet during arrivals for the screening of the film "La venue de l'avenir" (Colors of Time) Out of competition at the 78th Cannes Film Festival in Cannes, France, May 22, 2025. REUTERS/Sarah Meyssonnier/File Photo

[1/2]Aishwarya Rai poses on the red carpet during arrivals for the screening of the film "La venue de l'avenir" (Colors of Time) Out of competition at the 78th Cannes Film Festival in Cannes, France, May 22, 2025. REUTERS/Sarah Meyssonnier/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesBollywood couple fight for personality rights in New Delhi courtActors argue AI videos cause harm, should not be used in trainingCases could impact how YouTube allows video sharing with consentYouTube still shows Bollywood AI content with millions of viewsNEW DELHI, Oct 1 (Reuters) - In India, Bollywood stars are asking judges to protect their voice and persona in the era of artificial intelligence. One famous couple's biggest target is Google's

(GOOGL.O), opens new tab video arm YouTube.

Abhishek Bachchan and his wife Aishwarya Rai Bachchan, known for her iconic Cannes Film Festival red carpet appearances, have asked a judge to remove and prohibit creation of AI videos infringing their intellectual property rights. But in a more far-reaching request, they also want Google ordered to have safeguards to ensure such YouTube videos uploaded anyway do not train other AI platforms, legal papers reviewed by Reuters show.

Sign up here.

A handful of Bollywood celebrities have begun asserting their "personality rights" in Indian courts over the last few years, as the country has no explicit protection for those like in many U.S. states. But the Bachchans' lawsuits are the most high-profile to date about the interplay of personality rights and the risk that misleading or deepfake YouTube videos could train other AI models.

The actors argue that YouTube's content and third-party training policy is concerning as it lets users consent to sharing of a video they created to train rival AI models, risking further proliferation of misleading content online, according to near-identical filings from Abhishek and Aishwarya dated September 6, which are not public.

"Such content being used to train AI models has the potential to multiply the instances of use of any infringing content i.e. first being uploaded on YouTube being viewed by the public, and then also being used to train," the filings said.

Representatives for the Bachchans and Google spokespersons did not respond to Reuters' queries. The Delhi High Court last month asked Google's lawyer in court to submit written responses before the next hearing on January 15.

YouTube's India managing director, Gunjan Soni, last month described the platform as "the new TV for India". With around 600 million users, India is YouTube's biggest market globally, and it is popular for entertainment content like Bollywood videos.

LAWSUIT ALLEGES YOUTUBE VIDEOS ARE 'EGREGIOUS'Indian courts have already started to back Bollywood stars upset about generative AI content damaging their reputation. In 2023, a Delhi court restrained the misuse of Anil Kapoor's image, voice and even a catchphrase he often used.

Reuters is first to report details of the Bachchans' specific challenge against Google, which was contained in court filings spanning 1,500 pages where they mostly target little-known sellers for unauthorised physical merchandise like posters, coffee mugs and stickers with their photos, and even fake autographed pictures.

They are also seeking $450,000 in damages against Google and others, and a permanent injunction against such exploitation.

The lawsuits contain hundreds of links and screenshots of what they allege are YouTube videos showing "egregious", "sexually explicit" or "fictitious" AI content.

The judge in early September ordered 518 website links and posts specifically listed by the actors to be taken down, saying they caused financial harm to the couple and harmed their dignity and goodwill.

Reuters, however, found videos similar to the examples of infringing videos cited in Abhishek's papers on YouTube.

Among them: a clip showing Abhishek posing but then suddenly kissing a film actress using AI manipulation; an AI depiction of Aishwarya and her co-star Salman Khan enjoying a meal together while Abhishek fumes standing behind; and a crocodile chasing Abhishek as Khan tries to save him.

Khan was in a relationship with Aishwarya long before her marriage. His spokesperson did not respond to Reuters' queries.

AI CAN GENERATE BOLLYWOOD LOVE STORIESYouTube's data-sharing policy states creators can opt in to share their videos for training models of other AI platforms, like OpenAI, Meta and xAI. YouTube adds: "We can't control what a third-party company does" if users share videos for such training.

The Bachchans argue in their filings that if AI platforms are trained on biased content that portrays them in a negative manner and infringes their intellectual property rights, then AI models "are likely to learn all such untrue" information, leading to its further spread.

Eashan Ghosh, chair professor for intellectual property rights at the National Law University Delhi, said it would be difficult for actors to build a direct case against YouTube since their grievances are mostly with creators and personality rights infringement.

But "it wouldn't be beyond the pale for the court to nudge YouTube to write something into their user policies or set up a queue jump for celebrity claimants to get quicker responses to legal requests," he said.

YouTube in May disclosed that it had paid more than $2.4 billion to Indian creators in the last three years. The actors alleged that creators infringing their personality rights can make money when videos become popular.

Reuters found a channel on YouTube titled "AI Bollywood Ishq" that shares "AI-generated Bollywood love stories". Its 259 videos have garnered 16.5 million views. The most popular video with 4.1 million views shows an AI animation of Khan and Aishwarya in a pool, while another shows them on a swing.

In a tutorial, the channel explains it used simple text prompts to create an image via X's Grok AI and then turned it into a video using Chinese AI startup MiniMax's Hailuo AI. A Reuters test generated an AI video showing lookalikes of Bollywood stars Khan and Abhishek in a fistfight within five minutes.

Grok, MiniMax and the owner of YouTube channel @AIbollywoodishq did not respond to Reuters' queries. It was unclear whether the YouTube channel consented to sharing those videos for AI training.

"Content is made only for entertainment and creative storytelling," the channel's page said.

Reporting by Arpan Chaturvedi and Aditya Kalra; Editing by Jamie Freed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Arpan is a correspondent for Reuters based in New Delhi, where he reports from the courts in India. He joined Reuters in 2022, and has been a part of the companies coverage team reporting on court cases spanning aviation, mining, human rights and other public interest issues.

Aditya Kalra is the Company News Editor for Reuters in India, overseeing business coverage and reporting stories on some of the world's biggest companies. He joined Reuters in 2008 and has in recent years written stories on challenges and strategies of a wide array of companies -- from Amazon, Google and Walmart to Xiaomi, Starbucks and Reliance. He also extensively works on deeply-reported and investigative business stories.

  

Vancouver, BC:  September 30, 2025 – Uniserve Communications Corporation (the “Company” or “Uniserve”)(TSXV: USS)  a provider of IT solutions and services to business and residential customers in Canada wishes to announce its annual fiscal 2025 financial results.  Revenues for fiscal 2025 were $6,972K as compared to $6,439K for the prior fiscal year.  The annual fiscal 2025 Operating Loss was $1,681K compared to an Operating Loss of $239K for the prior fiscal year.  Net loss for fiscal 2025 was $1,899K as compared to Net loss of $191K for the prior fiscal year.  

About Uniserve

Uniserve delivers secure, reliable, and customized IT solutions that power your business forward. With offices in Vancouver, Calgary, and Waterloo, Uniserve provides a full suite of services across three core verticals: Data Centre Solutions, Managed IT Services, and Business Internet. Our data centre infrastructure ensures maximum uptime, security, and scalability - so when your IT runs right, your people and your business thrive.

This news release was prepared on behalf of the Board of Directors, which accepts full responsibility for its contents.

Learn more at www.uniserve.com or at www.sedarplus.ca.       

Kwin Grauer  

Chairman of the Board

Interim CEO

For more information please call 604-395-3961 or email [email protected].

Neither TSX Venture Exchange nor its Regulations Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Management has prepared this release and no regulatory authority has approved or disapproved the information contained herein. The statements contained in this news release that are not historical facts are forward looking statements. Such statements are based on management’s estimates, assumptions and projections using available information. Uniserve cautions that actual financial results could differ materially from the current expectations due to a number of factors.

Scan QR code to install app

Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.Risk DisclaimersThis website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

VANCOUVER, British Columbia--(BUSINESS WIRE)--Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) today announced that together with General Motors Holdings LLC (“GM”), its joint venture (the “JV”) partner in the Thacker Pass lithium project (“Thacker Pass” or the “Project”), the Company has reached a non-binding agreement in principle (the “First Draw Terms”) with the U.S. Department of Energy (the “DOE”) to advance the first draw of $435 million (the “First Draw”) on the previously announced $2.26 billion DOE loan (the “DOE Loan”).

The key provisions of the First Draw Terms include:

The DOE has agreed to defer $182 million of debt service over the first five years of the DOE Loan.

The DOE will receive:

5% equity stake in the Company through warrants to purchase common shares of the Company at an exercise price of $0.01 per share (the “LAC Warrants”) and

5% economic stake in the JV (the “JV Units”) through warrants to purchase non-voting, non-transferable equity interest of the JV with an exercise price of $0.01 per unit (the “JV Warrants”).

The Company will post an additional $120 million to DOE Loan reserve accounts, to be funded within 12 months of the DOE advancing First Draw.

GM will provide additional support to the Project by amending its lithium offtake agreement with the JV (the “Offtake Agreement”) to permit the JV to enter into additional third-party offtake agreements for certain remaining production volumes not forecasted to be purchased by GM.

Jonathan Evans, President and CEO of Lithium Americas said, “We greatly appreciate the support of the Administration, General Motors and our partners in advancing this vital world-class project. Together, we are onshoring large-scale U.S. lithium production, strengthening America’s supply chain, creating exceptional jobs and enhancing our long-term energy security and prosperity.”

Shilpan Amin, Senior Vice President Global Chief Procurement and Supply Chain Officer of General Motors said, “We’re confident in the Thacker Pass project, which will reduce U.S. dependence on imported lithium and can support domestic manufacturing across many industries, such as aerospace, defense and electrical grid resiliency, in addition to automotive. We are pleased to see it move forward and appreciate the Administration’s support as GM continues to build a secure, resilient supply chain.”

As contemplated by the First Draw Terms, in the event that the DOE exercises the JV Warrants in full, the JV economic interests will (prior to funding of the additional $120 million reserve accounts discussed above) be 59% held by Lithium Americas, which will continue to be the manager of the Project, 36% by GM and 5% by the DOE, with voting interest in the JV remaining 62% for Lithium Americas and 38% for GM. GM will have a call right to purchase, or cause the JV to purchase, the JV Warrants or, if the JV Warrants have been exercised by the DOE, the DOE’s JV Units (the “Call Right”) following Thacker Pass achieving substantial completion if a price can be agreed upon between GM and the DOE at the time of the Call Right. If GM and the DOE cannot agree on the price to exercise the Call Right, the JV Warrants or the DOE’s JV Units, as applicable, will be exchanged for common equity in the Company pursuant to a conversion ratio agreed upon by the DOE, GM and the Company, (the “LAC Warrant Conversion Rate”). The DOE will have a put right to cause GM to elect to either (i) purchase, or cause the JV to purchase, the DOE’s JV Warrants or DOE’s JV Units, as applicable at fair market value or (ii) cause the DOE’s JV Warrants or DOE’s JV Units, as applicable, to convert to shares of common equity in the Company at the then applicable LAC Warrant Conversion Rate. The DOE will also be granted the right to have an appointed representative as an observer at the JV Board meetings for so long as the DOE holds JV Warrants, or JV Units.

The expected total DOE Loan amount decreased to $2.23 billion. The DOE Loan principal of $1.97 billion remains the same, while the estimated capitalized interest during construction decreased to $256 million, due to a lower projected interest rate of 5.0%. The interest rate that will be applied to amounts drawn under the DOE Loan remains unchanged at the applicable long-dated U.S. Treasury rate from the date of each draw with 0% spread. The DOE Loan tenor remains approximately 24 years from date of First Draw. The First Draw of $435 million is expected in Q4 2025.

GM’s existing Offtake Agreement allows GM to purchase up to 100% of production volumes from Phase 1 and up to 38% of total production volumes of Thacker Pass for 20 years. GM retains the right of first offer on remaining Phase 2 production volumes and, following expiration of its offtake agreements, life of mine offtake rights, at market price, for a percentage of all volumes from Phase 1 and Phase 2 of the Project. The Offtake Agreement will be updated to allow the JV to enter into firm volume commitments with third parties for certain remaining Phase 1 production volumes not forecasted to be purchased by GM.

The First Draw Terms are preliminary in nature and are subject to, among other risks, the factors discussed below under “Forward-Looking Statements.” In each case, the First Draw Terms remain subject to negotiation and completion of definitive agreements, corporate approvals and other customary conditions. There can be no assurances that definitive documentation memorializing the First Draw Terms will be completed on the terms currently contemplated or at all.

The Company intends to rely upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange.

TRANSACTION ADVISORS

Goldman Sachs & Co. LLC is serving as financial advisor, while Vinson & Elkins LLP is serving as U.S. legal counsel and Cassels, Brock & Blackwell LLP as Canadian legal counsel to Lithium Americas.

ABOUT LITHIUM AMERICAS

Lithium Americas is developing Thacker Pass located in Humboldt County in northern Nevada, which hosts the largest known measured lithium resource (Measured and Indicated) and reserve (Proven and Probable) in the world. Thacker Pass is owned by a joint venture between Lithium Americas (holding a 62% interest and is the manager of the Project), and GM (holding a 38% interest). The Company is focused on advancing Phase 1 of Thacker Pass toward production, targeting nominal design capacity of 40,000 tonnes per year of battery-quality lithium carbonate. The Company and its engineering, procurement and construction management contractor, Bechtel, entered into a National Construction Agreement (Project Labor Agreement) with North America’s Building Trades Unions for construction of Thacker Pass. Construction is expected to create nearly 2,000 direct jobs, including 1,800 skilled contractors. Lithium Americas’ shares are listed on the Toronto Stock Exchange and New York Stock Exchange under the symbol LAC. To learn more, visit www.lithiumamericas.com or follow @LithiumAmericas on social media.

FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively referred to as “forward-looking statements” (“FLS”)). All statements, other than statements of historical fact, are FLS and can be identified by the use of statements that include, but are not limited to, words, such as “anticipate,” “plan,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “predict,” “proposes,” “potential,” “target,” “implement,” “schedule,” “forecast,” “intend,” “would,” “could,” “might,” “should,” “believe” and similar terminology, or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. FLS in this news release includes, but is not limited to, statements related to the DOE Loan and the First Draw Terms, including statements regarding definitive documentation memorializing the First Draw Terms, draw-down conditions on the DOE Loan, the expected timing for First Draw on the DOE Loan, if at all, and the outlook with respect to negotiations relating to the DOE Loan and the consequences related thereto; as well as other statements with respect to management’s beliefs, plans, estimates and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts.

FLS involves known and unknown risks, assumptions and other factors that may cause actual results or performance to differ materially. FLS reflects the Company’s current views about future events that, while considered reasonable by the Company as of the date of this news release, are inherently subject to significant uncertainties and contingencies. Accordingly, there can be no certainty that they will accurately reflect actual results. Although the Company believes that the assumptions and expectations reflected in such FLS are reasonable, the Company can give no assurance that these assumptions and expectations will prove to be correct.

Readers are cautioned that the foregoing lists of factors are not exhaustive. There can be no assurance that FLS will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. As such, readers are cautioned not to place undue reliance on this information, and that this information may not be appropriate for any other purpose, including investment purposes. The Company’s actual results could differ materially from those anticipated in any FLS as a result of the risk factors set out herein, and in the Company’s other continuous disclosure documents available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Readers are further cautioned to review the full description of risks, uncertainties and management’s assumptions in the aforementioned documents and other disclosure documents available on SEDAR+ and on EDGAR.

The FLS contained in this news release is expressly qualified by these cautionary statements. All FLS in this news release speaks as of the date of this news release. The Company does not undertake any obligation to update or revise any FLS, whether as a result of new information, future events or otherwise, except as required by law.

More News From Lithium Americas Corp.

October 01, 2025 12:01 AM EDT | Source: Predictmedix AI Inc.
Adaptive "digital brain" designed to cut risk, cost and timelines in the $70-billion clinical-trials market1

Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announced the launch of its Clinical-Trial AI Platform, an AI-driven solution intended to help pharmaceutical sponsors and contract research organizations (CROs) model, plan, and adapt clinical trials more efficiently.

A Digital Brain for Clinical Trials

Built on patented technology and the high-fidelity dataset generated by SmartHealth AI Stations, the platform is designed to function as a real-time digital support system for trial planning. It ingests and harmonizes diverse datasets—patients, protocols, sites, historical outcomes, and costs—and can update analyses as new data becomes available.

Key Features

Adaptive Simulation Engine — Runs "what-if" scenarios and refreshes projections as enrollment and site-performance information is received.Patient-Site Optimization — Uses AI to recommend patient-site matching that may improve recruitment and reduce dropouts.Cost & ROI Modeling — Proprietary algorithms estimate potential budget impact alongside predicted clinical outcomes.Interactive Dashboards — Executive and audit views visualize risk, cost, and patient flow with dynamic heatmaps and Sankey plots.Compliance-Integrated AI — Tracks data inputs and simulations to support audit and regulatory processes.Market Context

Industry analysts estimate the global clinical-trials market could exceed $70 billion by 20271, creating demand for tools that help sponsors reduce trial failures, improve patient recruitment, and manage costs. Predictmedix's platform is intended to address these needs with scalable, real-time analytics.

"Clinical development urgently needs smarter tools," said Dr. Rahul Kushwah, COO of Predictmedix. "Our platform is designed to highlight potential clinical trial challenges early, enabling sponsors to make informed adjustments that can help save time and resources and, ultimately, support faster delivery of new therapies."

Distinctive Capabilities

The platform is built around real-time adaptive AI, with automation applied across data ingestion, simulation, and outcome modeling.

Continuous Intelligence: Projections adjust as enrollment numbers, site performance, or protocol variables change.End-to-End Automation: From raw data to executive dashboards, workflows are automated to reduce manual reconciliation.Multi-Trial Orchestration: A single environment can simulate multiple protocols and allocate resources across a development portfolio.Cost-Outcome Integration: Financial modeling is embedded directly into clinical predictions for unified decision support.Validated Data Streams: The system draws on more than 500,000 SmartHealth scans, which internal and third-party assessments have measured at approximately 95 % accuracy for vital-sign detection; actual results may vary.Predictmedix is preparing to provide private demonstrations and explore paid pilot programs with pharmaceutical sponsors and CROs as opportunities emerge.

1https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-market

Detailed analysis of the company's direct comparables that are trading on CSE and/or TSXV can be found here : https://predictmedix.com/wp-content/uploads/2025/09/PMED.COMPARATIVEANALYSIS_SEP2025.pdf. Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/.

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268289

October 01, 2025 00:01 ET

 | Source:

Geotab Inc.

SYDNEY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Geotab, a global leader in connected vehicle solutions, today announced it has acquired the commercial operations of Verizon Connect’s telematics business in Australia, the United Kingdom, Ireland, Italy, France, Portugal, Poland, the Netherlands, and Germany. This strategic acquisition, which does not include Verizon’s Connect’s product, engineering, and other non-sales focused teams, significantly expands Geotab's global footprint and strengthens its market share, particularly within the crucial small to mid-sized fleet segment across key international markets.

The integration of Verizon Connect’s Australia and European commercial operations and expertise further enhances Geotab's commitment to delivering unparalleled value and comprehensive data insights to customers worldwide. The move expands Geotab's reach and tailored solutions for fleet businesses ensuring they have access to industry-leading telematics technology, AI and data insights, and local in-market support.

Geotab is pleased to welcome over 400 talented Verizon Connect employees from across Australia and Europe as part of the acquisition. Their expertise and dedication will be instrumental in accelerating Geotab's commitment to innovation and delivering robust, localised solutions for customers. The integration will be led by Matthew Kassel, Senior Vice-President, Strategic Acquisitions and Integration.

"This acquisition marks a pivotal moment for Geotab and the connected vehicle industry," said Neil Cawse, Founder, President and CEO of Geotab. "By welcoming Verizon Connect employees in Australia and Europe into the Geotab family, we are expanding our global reach and reinforcing the company’s commitment to serving the diverse needs of fleets of all sizes. We are excited about the exceptional opportunities this presents for customers, especially those with small to mid-sized fleets, to unlock greater efficiency, safety, and sustainability."

The integration of Verizon Connect’s commercial operations in Australia and Europe into Geotab is effective immediately. Customers of Verizon Connect in Australia and Europe can expect a seamless transition and continued access to high-quality telematics solutions, now backed by Geotab's extensive global infrastructure and innovation capabilities.

About Geotab

Geotab is a global leader in connected vehicle and asset management solutions, with headquarters in Oakville, Ontario and Atlanta, Georgia. Our mission is to make the world safer, more efficient, and sustainable. We leverage advanced data analytics and AI to transform fleet performance and operations, reducing cost and driving efficiency. Backed by top data scientists and engineers, we serve over 55,000 global customers, processing 100 billion data points daily from more than 5 million vehicle subscriptions. Geotab is trusted by Fortune 500 organizations, mid-sized fleets, and the largest public sector fleets in the world, including the US Federal government. Committed to data security and privacy, we hold FIPS 140-3 and FedRAMP authorizations. Our open platform, ecosystem of outstanding partners, and Geotab Marketplace deliver hundreds of fleet-ready third-party solutions. This year, we're celebrating 25 years of innovation. Learn more at www.geotab.com and follow us on LinkedIn or visit Geotab News and Views.

GEOTAB and GEOTAB MARKETPLACE are registered trademarks of Geotab Inc. in Canada, the United States and/or other countries.

Geotab Media Contact:

Nicole Riddle

Manager, Strategic Communications

[email protected]

Global private-equity giant KKR has expanded its partnership with the Abu Dhabi National Oil Company, acquiring a minority stake in ADNOC Gas Pipeline Assets.

That ADNOC subsidiary operates 38 gas pipelines and two export terminals in the United Arab Emirates. KKR did not disclose the value of the deal to CNBC.

The partnership follows ADNOC's 2019 oil pipelines deal with KKR and BlackRock, which opened the door to foreign direct investment across the region.

"This investment reflects KKR's commitment to expand partnerships and investment across the Middle East," said David Petraeus, partner at KKR and chairman of the KKR Global Institute and KKR Middle East. "The region's strong fundamentals, bold vision, and focused leadership offer increasingly attractive opportunities for global investors."

Earlier this year, the firm appointed former CIA Director Petraeus, who joined KKR in 2013, as chair of its Middle East operations and launched a dedicated investment team led by Julian Barratt-Due.

The transaction marks another milestone in KKR's expansion in the region. It acquired a stake in Dubai-based Gulf Data Hub, with a combined commitment from the two firms of more than $5 billion to fund the expansion of GDH's data center network. 

The ADNOC gas pipeline network, which links the company's upstream assets to domestic off-takers across the UAE, remains fully owned and operated by ADNOC. KKR has taken a minority stake, so ADNOC will retain control. KKR's stake — acquired through its managed accounts — is structured to yield long-term revenue, the company said.

The move expands KKR's over 16-year presence in the Middle East, with offices in the UAE and Saudi Arabia. The firm now manages more than $90 billion in infrastructure assets globally since launching its infrastructure strategy in 2008, according to information on its website.

SummaryCompaniesMove reflects doubts about whether equities bull run will continueNomura has appointed new head of US rates, co-head of FX and emerging markets businessExpects advisory business to have a better second halfTOKYO, Oct 1 (Reuters) - Japan's Nomura Holdings

(8604.T), opens new tab plans to beef up its interest rate and currency trading operations globally, believing increased market volatility will lift demand, a senior executive said.

The push reflects growing doubts around the longevity of the current equities bull run. When markets become more volatile, interest rate and foreign exchange products typically perform better, as clients hedge risk and rebalance their positions, generating higher trading flows.

Sign up here.

"Global equity markets are at all-time highs. U.S. markets - and within U.S. markets, a narrow set of stocks - have dominated as drivers of value," Christopher Willcox, the head of the firm's wholesale division, told Reuters in an interview.

"You would be wise to assume that can't go on forever and that at some point, there's an adjustment," he said.

Nomura declined to provide details on how much hiring would take place or current staff numbers for those operations.

NEW HIRESBut he noted that the group appointed a new head of U.S. rates in August - Moritz Westhoff, formerly of Bank of America - and a new co-head of its FX and emerging markets business, David Leigh, who joined from Deutsche Bank last November.

More personnel and capital will be directed to those teams, said Willcox, a former JP Morgan Asset Management CEO who joined Nomura in 2021 and became head of wholesale a year later.

Nomura's interest rate and exchange rate operations form the bulk of its macro products business, which has made up around 30% of the wholesale division's revenue in recent years. In the past business year, the division's revenue topped 1 trillion yen ($6.8 billion).

The push also reflects Nomura's efforts to build more diverse sources of income, given that its wholesale unit's performance has seen wild swings along with market conditions in the past.

"We view the macro business as counter-cyclical. In the global financial crisis, it was everyone's rates business that made all the money at the time when their securitised products businesses were shut down," Willcox said.

The securitisation of mortgage debt into financial instruments was among the core causes of the 2007-2009 global financial crisis.

Willcox also said Nomura's advisory business is likely to perform better in the second half of the year compared to the first half, as the public listing market in the U.S. has picked up and there is pent-up M&A demand in Japan.

Deals and capital raisings had been held back by uncertainty caused by U.S. President Donald Trump's sweeping tariffs, though this has eased somewhat with the signing of some trade agreements between the U.S. and other countries.

The wholesale division does not have planned any major acquisitions along the lines of Nomura's $1.8 billion purchase of Macquarie's U.S. and European public asset management businesses. But it is looking to diversify its business lines in areas where Nomura has existing expertise to make money regardless of market ups and downs.

Earlier in September, it launched a U.S. commercial real estate platform with a team hired from Barclays, which Willcox expects will contribute hundreds of millions of dollars to the top line over the next few years.

"We're asking where logically we can extend pre-existing expertise into new zones," Willcox said.

"And there's lots of them, it's not like we're running out of things to do."

($1 = 147.9700 yen)

Reporting by Anton Bridge and Miho Uranaka; Editing by Edwina Gibbs

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Cullen Dumps 6.6M KVUE Shares Worth $149.5 MillionCullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue (KVUE -0.77%) for the period ended Q2 2025. The transaction was valued at an estimated $149.46 million.

What happenedCullen Capital Management, LLC reported in a September 30, 2025SEC filingthat it reduced its position in Kenvue by 6,565,339 shares during Q2 2025. The estimated value of the shares sold was $149.46 million, based on the average closing price for the quarter. After the trade, Cullen retained 2,484,940 shares valued at $52.01 million as of Q2 2025.

What else to knowThe fund trimmed its Kenvue stake, which now represents 0.6% of 13F assets under management as of June 30, 2025.

Top holdings after the filing:

JPM: $303.61 million (3.5% of AUM) as of Q2 2025.CSCO: $279,989,672 (3.1889% of AUM) as of June 30, 2025.BAC: $260,614,250 (2.9682% of AUM) as of June 30, 2025.NVS: $253.74 million (2.9% of AUM) as of 2025-06-30.DUK: $241,854,363 (2.7545% of AUM) as of June 30, 2025.As of September 29, 2025, shares were priced at $16.34, down 29.4% over the past year, lagging the S&P 500 by 42.63 percentage points

Company OverviewMetricValueRevenue (TTM)$15.14 billionNet Income (TTM)$1.42 billionDividend Yield5.07%Price (as of market close 9/29/25)$16.34Company SnapshotKenvue Inc. generates revenue through a diversified portfolio of consumer health products, including over-the-counter medicines, skin and beauty care, and essential health items under brands such as Tylenol, Neutrogena, and Listerine.

The company operates worldwide through three segments: Self Care, Skin Health and Beauty, and Essential Health.

Kenvue Inc. offers healthcare, personal care, and wellness products globally.

Kenvue Inc. is a global consumer health company with a broad portfolio of well-established brands and a strong presence in the over-the-counter and personal care markets. Its strategic focus on essential health and self-care positions it competitively within the consumer defensive sector.

Foolish takeCullen Capital reduced Kenvue’s stake to 0.6% of assets under management after selling 6.6 million shares. This is notable because KVUE stock has fallen nearly 30% over the past year, and has badly lagged the S&P 500 by about 43 percentage points.

Institutions trim for many reasons, from portfolio rebalancing to risk control. Still, the consumer health sector is typically defensive, and KVUE’s underperformance shows that not all staples are immune to market headwinds. Kenvue continues to generate $1.4 billion in profit and offers a 5.07% dividend yield, underscoring its appeal to income-focused investors.

Looking ahead, the key question lies in whether this weakness reflects turbulence or a deeper challenge to Kenvue’s growth and margin profile. Investors should monitor whether Kenvue can deliver stabilized earnings and sustain its dividend. If not, more institutions may follow Cullen’s lead.

Glossary13F assets under management (AUM):The total value of securities reported by institutional investment managers in quarterly SEC Form 13F filings.
Dividend yield:The annual dividend payment divided by the stock's current price, expressed as a percentage.
Quarter (Q2 2025):The second three-month period of a company's fiscal year, here referring to April–June 2025.
Top holdings:The largest investments in a fund's portfolio, typically by market value or percentage of assets.
Consumer defensive sector:Industry group including companies providing essential goods, like food, beverages, and household products, less sensitive to economic cycles.
Over-the-counter medicines:Drugs available without a prescription, used to treat common health issues.
Portfolio:A collection of investments held by an individual or institution.
Lagging the S&P 500:Underperforming the S&P 500 index, meaning a lower return compared to this benchmark.
TTM:The 12-month period ending with the most recent quarterly report.

Bank of America is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Trie has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cisco Systems, JPMorgan Chase, and Kenvue. The Motley Fool recommends Duke Energy and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.

October 01, 2025 00:34 ET

 | Source:

Norwegian Cruise Line

New York, United States, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Editor-in-Chief of Cruise Critic, Colleen McDaniel, Shares the Benefits of Off-Season Cruises to the Mexican Riviera, Bahamas and Caribbean

With fall officially underway and temperatures dropping nationwide, travelers are already thinking about escaping to sunny destinations for a last-minute vacation. Recently, Cruise Critic Editor-in-Chief of Colleen McDaniel teamed up with

Norwegian Cruise Line to discuss the benefits of off-season cruising to the Mexican Riviera, Bahamas and Caribbean; what’s new in the industry and why vacations at sea are the perfect getaway for families and travelers alike.
A video accompanying this announcement is available at:

Travel Expert Colleen McDaniel and Norwegian Cruise Line Discuss Off-Season Cruising Destinations
Off-season cruises during the cooler months offer smaller crowds, better deals and the chance to visit warm-weather destinations without the summer rush. Travelers can enjoy a more relaxed pace at popular ports, making it easier to book shore excursions, dine at top restaurants and explore destinations with ease all at a greater value.
With 18 ships sailing to the Mexican Riviera, Bahamas and Caribbean from 11 convenient homeports, including Los Angeles and San Diego, Calif.; Miami, Tampa, Port Canaveral and Jacksonville, Fla.; Galveston, Texas; New Orleans; New York City and more, Norwegian Cruise Line gives travelers the freedom and flexibility to design their dream cruise vacation with a variety of warm-weather adventures.Whether travelers are interested in a quick three-day Bahamas getaway , or a week-long Mexican Riviera cruise enjoying margaritas in ports like Puerto Vallarta and Cabo San Lucas, there is something for every type of traveler. NCL also offers a variety of seven-day voyages to the Caribbean, where guests can island hop from one pristine beach to the next. Plus, many of Norwegian’s Bahamas and Caribbean sailings visit the Company’s top guest-rated private island, Great Stirrup Cay, which will debut new enhancements later this year including a new pier and a 1.4 acre pool area complete with swim-up bars and a splash pad for families with young children.
With cruise fares starting from $249 per person, guests can maximize their vacation with NCL’s More At Sea package, which includes over $2,000 in value with perks like unlimited open bar, specialty dining, Wi-Fi and shore excursion credits.
To start planning your next trip, visit NCL.com

About Colleen McDaniel
Colleen McDaniel is Editor-in-Chief of Cruise Critic, the world’s largest online cruise resource. She considers cruising to be a true passion, having traveled the world by water – from Alaska, the Caribbean and Hawaii, to Europe’s rivers, Antarctica and Africa – on ships of all shapes and sizes. She’s regularly quoted as a cruise expert in media outlets across the country, including outlets like The Associated Press, Good Morning America, CNN, FOX Business, CNBC, The New York Times, Travel + Leisure and Skift. Cruise Critic is the world’s largest cruise reviews and information site, offering a comprehensive resource for cruise travelers — from first-time cruisers to avid cruise enthusiasts. The site features more than 50M+ opinions, reviews & photos and hosts the world’s largest online cruise community. Cruise Critic is a subsidiary of Tripadvisor, Inc.

About Norwegian Cruise Line
As the innovator in global cruise travel, Norwegian Cruise Line has been breaking the boundaries of traditional cruising for 58 years. Most notably, the cruise line revolutionized the industry by offering guests the opportunity to design their ideal vacation on their preferred schedule with no assigned dining and entertainment times and no formal dress codes. Today, the company invites guests to ‘Experience More at Sea’ by providing them with more to see, more to do, more to enjoy, and more value on their vacation. To further deliver guests with more value, NCL’s ‘More At Sea’ package provides added benefits and inclusions such as unlimited open bar; specialty dining credits; high-speed Wi-Fi; shore excursions credits; as well as free airfare and third and fourth guests sail free on select sailings. Its fleet of 20 contemporary ships sail to nearly 350 of the world’s most desirable destinations, including Great Stirrup Cay, the company’s private island in the Bahamas and its resort destination Harvest Caye in Belize. Norwegian Cruise Line not only provides superior guest service from land to sea but also offers a wide variety of award-winning entertainment and dining options as well as a range of accommodations across the fleet, including solo-traveler staterooms, club balcony suites and The Haven by Norwegian, the company’s ship-within-a-ship concept.

For additional information or to book a cruise, contact a travel professional, call 888-NCL-CRUISE (625-2784) or visit www.ncl.com.

For the latest news and exclusive content, visit the NCL Newsroom and follow Norwegian Cruise Line on Facebook, Instagram, Tik Tok and YouTube @NorwegianCruiseLine; and Twitter @CruiseNorwegian.

Norwegian Cruise Line

Norwegian Cruise Line
Norwegian Cruise Line

Contact Data

Director of Media Planning
Dante Muccigrosso
DS Simon Media
[email protected]

BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in threat detection and exposure management, today announced the launch of its new local entity and local instance of its platform in the United Arab Emirates (UAE), marking a significant strategic investment in the region. This expansion reinforces Rapid7’s long-term commitment to the UAE’s government, businesses, and partner ecosystem to support the nation’s digital transformation and cyber resilience goals.

Rapid7 has already delivered on its promise to invest in the region and build trusted, locally-aligned capabilities. The company recently achieved DESC certification, meeting the rigorous security standards to support government entities and other regulated industries with digital transformation projects. In addition, Rapid7 has opened an office in Dubai, acknowledging that the UAE cybersecurity market is projected to reach $4.51 billion by the end of 2025 and that cybersecurity is a national priority for the UAE government. Rapid7 aims to provide localized support for organizations that are focused on developing security programs to protect critical digital infrastructure in the region.

"Dubai is a hub for innovation, thanks to its strategic investments in digital infrastructure, supportive government policies, and a comprehensive ecosystem of tech hubs. Cybersecurity is a vital component in enabling those initiatives," said Corey Thomas, CEO of Rapid7. "Establishing a UAE entity and data sovereignty demonstrates Rapid7's commitment to the region's cyber vision. Our investment in dedicated cloud infrastructure enables organizations in the UAE and the Gulf to access our world-class cybersecurity platform. We look forward to building partnerships with local businesses and governments to better protect the UAE's digital future."

Trusted partnership, local commitment
Data sovereignty is both a strategic imperative and a regulatory expectation with the UAE. Rapid7 is proud to have already achieved certification from the Dubai Electronic Security Center (DESC). DESC provides a critical framework for managing cyber risks and ensuring that government entities and organizations operating in the UAE uphold the highest standards of cybersecurity.

Rapid7's compliance with this framework, and the operation of a local instance, demonstrates a firm commitment to supporting the UAE's national cybersecurity priorities. This enables Rapid7 customers to meet regulatory requirements with confidence while keeping their data securely within national borders.

"Data sovereignty is a critical national issue. Rapid7's establishment of a local presence in the UAE shows its commitment to regional priorities and support for local data policies. It sends a clear message that Rapid7 is dedicated to enabling secure digital growth on local terms,” said Nasar Saddiq, Regional Manager, Middle East and Africa at Rapid7. "For Rapid7, it’s not just setting up an office, we're continuing our foundation of trust, partnership, and shared success."

Excellence in exposure management
As part of this launch, Rapid7 will deliver

Exposure Command, an attack surface visibility solution, helping organizations across the UAE manage vulnerabilities, applications, and cloud security. Rapid7 has received several recognitions for this offering, including the recent placement of

Leader in the IDC MarketScape: Worldwide Exposure Management 2025 Vendor Assessment and Strong Performer in the 2025 Forrester Wave™ for Unified Vulnerability Management (UVM). These recognitions demonstrate Rapid7's ability to provide organizations with visibility, prioritization, remediation, and response to ensure a robust security posture.

"Our platform provides clarity, speed, and insight in the moments that matter most," said David Howorth, EMEA General Manager at Rapid7. "As the UAE's digital economy grows, so too must the security programs that support it. We are committed to helping companies of all sizes navigate this new era securely and confidently."

Rapid7's "Secure the Attack Surface" approach is uniquely suited to support the UAE's transformation by offering:

Context-driven visibility across complex digital environmentsCost-effective risk reduction through automation and managed servicesScalable, localized support aligned with regional compliance standardsProactive threat prevention backed by global threat intelligence Rapid7 at GITEX 2025
GITEX Global 2025 is the premier exhibition showcasing tech innovation within the UAE. Corey Thomas will attend and present at GITEX in the Dubai World Trade Center on October 15 in the Cybersecurity theatre discussing ‘Cybersecurity, AI, and the Business of Trust.’ Visit Rapid7 at Stand No- H23-11, Hall 23.

To learn more about how Rapid7’s Exposure Command offering anticipates threats, prioritizes remediation, and enforces compliance, visit: https://www.rapid7.com/products/command/exposure-management/

About Rapid7
Rapid7, Inc. (NASDAQ: RPD) is on a mission to create a safer digital world by making cybersecurity simpler and more accessible. We empower security professionals to manage a modern attack surface through our best-in-class technology, leading-edge research, and broad, strategic expertise. Rapid7’s comprehensive security solutions help more than 11,000 global customers unite cloud risk management with threat detection and response to reduce attack surfaces and eliminate threats with speed and precision. For more information, visit our website, check out our blog, or follow us on LinkedIn or X.

Rapid7 Media Relations
Alice Randall
Director, Global Corporate Communications
[email protected]
(857) 216-7804

Rapid7 Investor Contact
Ryan Gardella / Ryan Flanagan
ICR, Inc
[email protected]
(617) 865-4277

SummaryCompaniesEk's legacy includes reshaping music industry with streaming modelCriticism over Ek's investment in AI-controlled combat dronesEk to remain involved in Spotify as executive chairSTOCKHOLM, Oct 1 (Reuters) - When Daniel Ek founded Spotify

(SPOT.N), opens new tab in 2006, a viable music product was a "moon shot." The global music industry was struggling with years of declining sales, online music piracy was rampant, and services like Apple's

(AAPL.O), opens new tab iTunes were pricey.

Ek believed if access to music was as easy as turning on a tap - in a way that was legal and fair to artists - users would come. The key was streaming, not downloads, an idea that revolutionized the industry and catapulted Spotify into a $140 billion music powerhouse.

Sign up here.

The serial entrepreneur, who announced on Tuesday he will step down as Spotify's CEO next year, has his sights set on building the next Spotify — albeit not in the music industry. Ek wants to focus on technology that drives "progress in areas that matter most to society."

"I am often asked, 'How do we build more Spotifys out of Europe?'" Ek said in a note to Spotify employees on Tuesday. "That’s why several years ago, I announced my intention to help create more of these supercompanies - companies that are developing new technologies to tackle some of the biggest challenges of our time."

Ek has pledged to invest through his venture capital firm Prima Materia 1 billion euros ($1.18 billion) of his own wealth in European “moonshot” projects — early-stage startups in deep technology, AI, and climate and health tech.

The billionaire's

motto is to, opens new tab not just invest, but to build businesses for the long term, driven by his belief that global champions can be built in Europe.

"I’ll share more about how I’ll put some of my builder energy there," Ek said in the letter, referring to his outside engagements. "But today is about Spotify."

WAR TECH SPARK ARTIST BACKLASHIn 2018, Ek co-founded Neko Health to help people stay healthy through preventive measures and early detection. The company has raised $325 million in total funding.

Ek has also invested in Germany's Helsing, a maker of AI-controlled combat drones that has received over a billion dollars to become the largest defence startup in Europe, valued at $12 billion. This investment, though, has drawn criticism.

Music groups including Massive Attack, King Gizzard & the Lizard Wizard, and Hotline TNT removed their music from Spotify in protest.

"Music and weapons are not a good mix," said Simon Dyson, analyst at Omdia. With some high-profile artists pulling their music from the service, "the sounds of protest are starting to become a distraction," he said.

The company did not immediately respond to an email seeking comment.

Ek has weathered criticism before, from artist pay disputes to controversies around Spotify’s podcast investments. Supporters credit him with creating a legal model that drew listeners away from piracy, but critics note Spotify's outsized influence on artists, which has often translated to inequity for independent labels.

FROM CODER TO MUSIC INDUSTRY DISRUPTORAs a 23-year-old coder, Ek started Spotify to challenge online music piracy with a legal alternative, something even big music companies were struggling to address.

When he steps down from the CEO role next year to become executive chair, he will pass the reins of a music giant to his two long-trusted aides, Gustav Soderstrom and Alex Norstrom.

Ek, now 42, grew up in a Stockholm suburb and worked in several startups before teaming up with co-founder Martin Lorentzon to start Spotify.

His proposition - music funded by subscriptions and ads - helped redirect fans from piracy and pulled labels, artists and advertisers into a single marketplace.

Under Ek, Spotify pushed three big levers that reshaped the business: price-disciplined subscriptions, algorithmic playlists that could mint hits overnight, and an ever-widening content range, from podcasts to audiobooks.

Ek’s legacy is visible in Spotify user habits - a monthly fee that millions treat as a utility, playlists that serve as cultural gatekeepers, and podcasts that have become a daily routine.

A Netflix miniseries, "The Playlist", showcased the birth and rise of Spotify in 2022.

Although Ek plans to focus on building other companies, he intends to stay involved in Spotify.

"I will be more involved than a typical U.S. chairman, so think of it a little bit like moving from a player to a coach," Ek told journalists on Tuesday.

($1 = 0.8511 euros)

Reporting by Supantha Mukherjee in Stockholm; Editing by Sayantani Ghosh and Lisa Shumaker

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Supantha leads the European Technology and Telecoms coverage, with a special focus on emerging technologies such as AI and 5G. He has been a journalist for about 18 years. He joined Reuters in 2006 and has covered a variety of beats ranging from financial sector to technology. He is based in Stockholm, Sweden.